Replicative capacity results complicated by minority wild-type virus
1 September 2003. Related: Conference reports, Virology, Drug resistance.
Drug resistance
Tenofovir, resistance and K65R and concomitant nucleosides
1 September 2003. Related: Conference reports, Antiretrovirals, Drug resistance.
Response to STI is determined by virus rather than immunological response
1 September 2003. Related: Conference reports, Drug resistance.
Why resistance rarely develops with viral suppression <50 copies/mL
1 September 2003. Related: Conference reports, Drug resistance.
Long-term persistence of distinct mutations in genital tract
1 September 2003. Related: Conference reports, Women's health, Drug resistance.
Resistance summary of new PIs: atazanavir and tipranavir
1 September 2003. Related: Drug resistance.
Study reveals new reverse transcriptase mutations
1 May 2003. Related: Drug resistance.
Nevirapine resistance – the cautionary tales continue
1 April 2003. Related: Conference reports, Pregnancy, Drug resistance.
Subtle decreases in stavudine (d4t, Zerit) phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine (AZT, Retrovir)-experienced patients
1 March 2003. Related: Drug resistance.
Medical care providers have very limited knowledge of resistance-associated drug mutations
1 March 2003. Related: Drug resistance.
Inhibitory quotient useful as indicator of effective protease inhibitor therapy
1 March 2003. Related: Drug resistance.
The advantages of fosamprenavir; comparing saquinavir/r to lopinavir/r; reducing viral load to <3 copies; AZT-d4T cross resistance; and rising HCV rates
1 February 2003. Related: Conference reports, Antiretrovirals, Treatment strategies, Hepatitis coinfection, Drug resistance.
Enfuvirtide (T-20): predicting success and modelling survival benefits
1 February 2003. Related: Conference reports, Antiretrovirals, Drug resistance.
M184V is associated with decreased development of TAMs
13 October 2002. Related: Drug resistance.
Short resistance reports from Seville
11 September 2002. Related: Conference reports, Drug resistance.
Review of phenotypic resistance testing data presented at the XI International HIV Drug Resistance Workshop
11 September 2002. Related: Conference reports, Drug resistance.
Study of MTCT programme finds resistance in women on two doses of monotherapy
11 September 2002. Related: Conference reports, Pregnancy, Drug resistance.
Amprenavir mutations may significantly affect LPV resistance
11 June 2002. Related: Antiretrovirals, Drug resistance.
Resistance mutations continue to accumulate with low-level viral increases
11 June 2002. Related: Drug resistance.
Resistance to template-analogue inhibitors linked to impaired replication
11 June 2002. Related: Drug resistance.
Abacavir treatment limited by prior NRTI exposure
11 June 2002. Related: Antiretrovirals, Drug resistance.
Phenotypic resistance to ddI is less frequent than resistance to ZDV, 3TC and abacavir
9 January 2002. Related: Conference reports, Drug resistance.
Secondary mutations in HIV-1 protease predict treatment failure in naive patients
9 December 2001. Related: Antiretrovirals, Drug resistance.
HIV drug resistance can develop under HAART at low levels of viraemia
2 November 2001. Related: Conference reports, Drug resistance.
GigaHAART study shows benefit of treatment interruption prior to treatment with >7 drugs in highly treatment experienced patients
2 November 2001. Related: Conference reports, Drug resistance.
Patients refractory to HIV treatment require close monitoring
2 November 2001. Related: Drug resistance.
Report on salvage therapy from the 39th annual meeting of the IDSA
2 November 2001. Related: Antiretrovirals, Drug resistance.
Resistance to nevirapine differs by HIV-1 subtype
1 October 2001. Related: Pregnancy, Drug resistance.
Anti-HIV immune responses and partial viral suppression
30 July 2001. Related: Conference reports, Drug resistance.
HIV resistance, phenotypic drug susceptibility and viral fitness
30 July 2001. Related: Conference reports, Drug resistance.
SWATCH – alternating antiretroviral regimens
30 July 2001. Related: Conference reports, Drug resistance.
Structured treatments interruptions
30 July 2001. Related: Conference reports, Drug resistance.
Importance of additional active drugs for NNRTI-naive patients using NNRTI-based salvage regimens
30 July 2001. Related: Conference reports, Drug resistance.
NNRTI and PI drug plasma levels are as critical as drug sensitivity in achieving treatment success in antiretroviral experienced patients
30 July 2001. Related: Conference reports, Drug resistance.
Increased prevalence of transmission of drug resistant HIV and reduced response in newly infected subjects in nine US cities
30 July 2001. Related: Conference reports, Drug resistance.
Role of codon-69 variants in reduced susceptibility to nucleoside analogues
30 July 2001. Related: Conference reports, Drug resistance.
Selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug naive people
30 July 2001. Related: Conference reports, Drug resistance.
Nucleoside resistance pathways may differ between HIV-1 and HIV-2
30 July 2001. Related: Conference reports, Drug resistance.
Role of Y318F mutation in NNRTI resistance
30 July 2001. Related: Conference reports, Drug resistance.
Prevalence of the T215Y mutation in HIV type 1-infected pregnant women in a New York cohort, 1995-1999
30 July 2001. Related: Pregnancy, Drug resistance.
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus
30 July 2001. Related: Basic science and immunology, Drug resistance.
HIV drug resistance is increasing in the UK
30 June 2001. Related: Drug resistance, Other news.
Drug resistant HIV spreading in UK
17 May 2001. Related: Drug resistance.
Paediatric treatment issues at the 8th CROI
17 April 2001. Related: Conference reports, Paediatric care, Drug resistance.
HIV evolves independently in blood and CSF
17 April 2001. Related: Drug resistance.
First European guidelines for HIV-1 drug resistance testing (2001)
17 March 2001. Related: Guidelines, Drug resistance.
Update on HIV drug resistance
17 March 2001. Related: Conference reports, Drug resistance.
MDR resistance transmission increases in the UK
17 December 2000. Related: Conference reports, Drug resistance.
Treatment interruption and salvage therapy
17 October 2000. Related: Conference reports, Drug resistance.
Tenofovir (PMPA), defining cross-resistance profiles
16 July 2000. Related: Conference reports, Drug resistance.
Mycophenalate mofetil in patients with advanced disease and multidrug resistant HIV
16 July 2000. Related: Conference reports, Drug resistance.
Hydroxyurea is active in vitro against multidrug-resistant HIV
16 July 2000. Related: Conference reports, Drug resistance.
ABT-378/r (Lopinavir): defining a resistance profile and the effects of resistance on virological response in experienced patients
16 July 2000. Related: Conference reports, Drug resistance.
Phenotypic resistance testing improves response to therapy: final analysis of VIRA3001
16 July 2000. Related: Conference reports, Drug resistance.
Continued benefits from protease inhibitor based therapy despite virological failure
16 July 2000. Related: Conference reports, Drug resistance.
Do resistance mutations disappear off therapy?
16 July 2000. Related: Conference reports, Drug resistance.
Selection of PI mutations during slow decay of VL and resistance after PI failure
16 July 2000. Related: Conference reports, Drug resistance.
Thymidine analogues mutations (TAMS) and other NA-related resistance mutations
16 July 2000. Related: Conference reports, Drug resistance.
Immune response may persist after emergence of protease inhibitor-resistant HIV
16 July 2000. Related: Drug resistance.
HIV drug resistance testing: update
15 June 2000. Related: Guidelines, Drug resistance.
Clinical studies of indinavir/ritonavir as salvage therapy
15 May 2000. Related: Conference reports, Drug resistance.
Indinavir plus ritonavir: might exposure to higher levels of indinavir overcome protease resistant HIV and prove useful to ‘rescue’ previously failed protease inhibitor based combinations?
15 May 2000. Related: Conference reports, Drug resistance.
HIV-positive women, pregnancy and newborns
14 April 2000. Related: Conference reports, Pregnancy, Drug resistance.
Non-clade B virus: epidemiology, testing strategies and resistance
14 April 2000. Related: Conference reports, Drug resistance.